Skip to main content
Clinical Trials/NL-OMON34649
NL-OMON34649
Completed
Phase 2

eft Ventricular Lead Acute Clinical Study - LILAC

Boston Scientific0 sites10 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Heart Failure - Cardiac decompensation
Sponsor
Boston Scientific
Enrollment
10
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients who are scheduled to receive (new implant or upgrade) either CRT\-P or CRT\-D system based on physician discretion
  • Patients who are scheduled to have an LV lead implantation based on physician discretion
  • Patients who are expected to tolerate approximately 30 minutes of study testing procedures per physician discretion
  • Patients who are willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational center
  • Patients whose age is 18 years or above, or of legal age to give informed consent specific to state and national law

Exclusion Criteria

  • Patients who are allergic to the contrast media used in the study
  • Patients who have a history of pocket or device related infection
  • Patients who have any previous cardiac surgery within the last 3 months
  • Patients who have concomitant cardiac surgery
  • Patients who have unstable angina
  • Patients who have myocardial infarction within the last 3 months
  • Patients who are dependent on IV inotropes
  • Patients who are in acute cardiac failure crisis
  • Women of childbearing potential who are, or might be, pregnant at the time of the study (method of assessment upon physician\*s discretion)
  • Patients whose age is more than 80 years

Outcomes

Primary Outcomes

Not specified

Similar Trials